Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER |
| 1 |
| Sep 9, 2025 |
| clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03844464 | Safety and Efficacy of Lorbrena | completed | — | 1,290 | PfizerINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT02819024 | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography | completed | N/A | 6 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05517083 | Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer | completed | N/A | 41 | Pusan National University HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04951154 | A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer | completed | — | 33 | Janssen Research & Development, LLCINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01951482 | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02623712 | The Watch the Spot Trial(WTS) | completed | N/A | 34,686 | Kaiser PermanenteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121387 | A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer | completed | — | 221 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | completed | Phase 1 | 146 | MacroGenicsINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04206072 | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC | completed | Phase 2 / Phase 3 | 362 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07111104 | Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma(ARIS) | completed | — | 350 | Hopitaux Prives de Metz, Groupe UNEOSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 41 | Yale UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07065422 | AI Models for Predicting Occult Pleural Dissemination in NSCLC | completed | — | 326 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration(FIGHT-210) | completed | Phase 2 | 8 | Incyte CorporationINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT06617390 | A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments(RECAP) | completed | — | 1,041 | Daiichi SankyoINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT00243867 | Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer | completed | Phase 3 | 518 | American Regent, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05212285 | Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer | completed | — | 469 | Fudan UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099105 | Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer(SP vs MP robot) | completed | — | 339 | Korea University Guro HospitalOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT00199615 | Follow-up of Patients With Curative-intent Surgical Resection for NSCLC | completed | N/A | 73 | University Hospital, LimogesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04830826 | A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China(ADDRESS) | completed | — | 1,490 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05303493 | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma | completed | Phase 1 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02392455 | VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) | completed | — | 817 | Boehringer IngelheimINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 26 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT00284778 | Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer | completed | Phase 3 | 150 | University Hospital, LimogesOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT05546905 | A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) | completed | — | 206 | Pierre Fabre MedicamentINDUSTRY | 5 | Jul 22, 2025 | clinicaltrials |
| NCT00199758 | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 227 | University Hospital, LimogesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04120454 | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT07053215 | Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC | completed | N/A | 60 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT06054152 | CX3CR1+T Cell Predict Immunotherapy Efficacy | completed | — | 150 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036016 | Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1 | completed | — | 67,818 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT02299141 | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03885765 | Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping(CLIPPCAIR) | completed | — | 160 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT02705820 | Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy(SWIPE) | completed | Phase 2 | 48 | Bank of Cyprus Oncology CentreOTHER | 1 | Jun 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2025source: clinicaltrials